

Miao Xu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5493158/publications.pdf>

Version: 2024-02-01

27
papers

3,536
citations

471509

17
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

6602
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 196-208.	9.1	147
2	A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. <i>SLAS Discovery</i> , 2022, 27, 86-94.	2.7	16
3	The next major emergent infectious disease: reflections on vaccine emergency development strategies. <i>Expert Review of Vaccines</i> , 2022, 21, 471-481.	4.4	9
4	Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. <i>Emerging Microbes and Infections</i> , 2022, 11, 829-840.	6.5	25
5	Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 69.	17.1	19
6	Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV. <i>Emerging Microbes and Infections</i> , 2022, 11, 1145-1153.	6.5	17
7	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	3.3	10
8	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	4.8	10
9	Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice. <i>Virology Journal</i> , 2022, 19, .	3.4	3
10	Therapeutic Effect of Subunit Vaccine AEC/BC02 on Mycobacterium tuberculosis Post-Chemotherapy Relapse Using a Latent Infection Murine Model. <i>Vaccines</i> , 2022, 10, 825.	4.4	17
11	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 39-51.	9.1	923
12	Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 629-637.	6.5	118
13	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. <i>Emerging Microbes and Infections</i> , 2021, 10, 1598-1608.	6.5	76
14	Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. <i>ACS Nano</i> , 2021, 15, 2738-2752.	14.6	143
15	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	4.8	81
16	Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 365-373.	4.4	139
17	COVID-19 vaccines: progress and understanding on quality control and evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 199.	17.1	21
18	The first Chinese national standards for SARS-CoV-2 neutralizing antibody. <i>Vaccine</i> , 2021, 39, 3724-3730.	3.8	8

#	ARTICLE	IF	CITATIONS
19	Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. <i>Nature Protocols</i> , 2020, 15, 3699-3715.	12.0	291
20	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. <i>Frontiers of Medicine</i> , 2020, 14, 746-751.	3.4	57
21	Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models. <i>Emerging Microbes and Infections</i> , 2020, 9, 2606-2618.	6.5	28
22	Structure of Epstein-Barr virus tegument protein complex BBRF2-BSRF1 reveals its potential role in viral envelopment. <i>Nature Communications</i> , 2020, 11, 5405.	12.8	11
23	Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. <i>Cell</i> , 2020, 182, 713-721.e9.	28.9	639
24	Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. <i>Emerging Microbes and Infections</i> , 2020, 9, 680-686.	6.5	638
25	Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection. <i>Vaccine</i> , 2019, 37, 4477-4484.	3.8	17
26	Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 597-603.	3.1	39
27	The development and preliminary evaluation of a new <i>Mycobacterium tuberculosis</i> vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 59, 42-52.	2.7	30